Full Text
The Full Text of this article is available as a PDF (347.1 KB).
References
- 1.Kumar S, Noronha V, Chu E (2005) Antimetabolites. In Cancer: Principles and Practice of Oncology. 7th Edition. Vincent T DeVita Jr, Samuel Heltman, Steven A Rosenberg (eds) Lippincott Williams & Wilkins. pp 360–361
- 2.Rubinstein L.J., Herman M.M., Long T.F., Wilbur J.R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer. 1975;35:291–305. doi: 10.1002/1097-0142(197502)35:2<291::AID-CNCR2820350202>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
- 3.Davidson A., Payne G., Leach M.O., et al. Proton magnetic resonance spectroscopy of the brain following high-dose methotrexate treatment for childhood cancer. Med Pediatr Oncol. 2000;35:28–34. doi: 10.1002/1096-911X(200007)35:1<28::AID-MPO5>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
- 4.Quinn C.T., Griener J.C., Bottiglieri T., et al. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol. 1997;15:2800–2806. doi: 10.1200/JCO.1997.15.8.2800. [DOI] [PubMed] [Google Scholar]
- 5.Fisher M.J., Khademian Z.P., Simon E.M., et al. Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. Am J Neuroradiol. 2005;26:1686–1689. [PMC free article] [PubMed] [Google Scholar]